Clinical trial
A Single-center, Randomized, Double-blind, Controlled Study Comparing the Efficacy and Safety of Pirfenidone Versus Placebo in the Treatment of Takayasu Arteritis on the Basis of Conventional Immunosuppressive Therapy
NCT07325357 is registered in ClinicalTrials.gov with Shanghai Zhongshan Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-center, Randomized, Double-blind, Controlled Study Comparing the Efficacy and Safety of Pirfenidone Versus Placebo in the Treatment of Takayasu Arteritis on the Basis of Conventional Immunosuppressive Therapy
- Lead sponsor
- Shanghai Zhongshan Hospital
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- December 20, 2025
- Completion date
- December 31, 2030
- Enrollment
- 92 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.